National Cancer Institute (NCI), shared Anthony Letai’s, Director of the National Cancer Institute, post on X:
“The RAS story shows why long-term investment in basic research matters. Decades of science and collaboration helped turn a once-elusive target into new possibilities for patients.
Quoting Anthony Letai:
“WATCH: For decades, RAS was considered one of cancer research’s most difficult targets. This new Your NCI video tells the story of how sustained the NCI investment, strong science, and collaboration helped change what was possible for patients.”
You can also read: Phase 3 RASolute 309 Trial Begins: RASONQUE Plus Zoldonrasib in First-Line RAS G12D PDAC
